Targeting the ATX–LPA pathway holds therapeutic potential because this signaling axis may promote the development of neurodegenerative diseases through multiple mechanisms involving mitochondrial dysfunction, oxidative stress, inflammation, and other processes. Here, ENPP2 is linked to neurodegenerative disease.